Skip to main navigation Skip to search Skip to main content

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

  • Emmanuel S. Antonarakis
  • , Se Hoon Park
  • , Jeffrey C. Goh
  • , Sang Joon Shin
  • , Jae Lyun Lee
  • , Niven Mehra
  • , Ray Mcdermott
  • , Núria Sala-Gonzalez
  • , Peter C. Fong
  • , Richard Greil
  • , Margitta Retz
  • , Juan Pablo Sade
  • , Patricio Yanez
  • , Yi Hsiu Huang
  • , Stephen D. Begbie
  • , Rustem Airatovich Gafanov
  • , Maria De Santis
  • , Eli Rosenbaum
  • , Michael P. Kolinsky
  • , Felipe Rey
    • Kun Yuan Chiu, Guilhem Roubaud, Gero Kramer, Makoto Sumitomo, Francesco Massari, Hiroyoshi Suzuki, Ping Qiu, Jinchun Zhang, Jeri Kim, Christian H. Poehlein, Evan Y. Yu

Research output: Contribution to journal › Article › peer-review

117   Link opens in a new tab Citations (Scopus)

Fingerprint

Dive into the research topics of 'Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases